viewCellmid Limited

Cellmid granted U.S. patent for midkine to treat heart failure


Cellmid Limited (ASX: CDY) has been granted a U.S. patent for the use of midkine as a treatment for heart failure which commonly follows non-fatal heart attacks.

The grant of patent application 11/720,983 entitled "Composition for treating or preventing myocardial disorder or heart failure" follows equivalent patents granted in Europe and Japan.

Cellmid’s patent portfolio currently includes 87 patents in 20 patent families, which cover the use of MK and anti-MK agents for therapeutic purposes in a number of diseases, as well as the use of MK as a diagnostic marker in cancer and other disorders.

In published studies using in vivo animal models, MK treatment following heart attack potently promotes new blood vessel growth in the affected tissue (angiogenesis), limits cardiac dysfunction, promotes ventricular tissue repair and increases long term survival rates. 

Significantly, MK is effective even where treatment initiation is delayed for weeks after infarct.

“This patent reinforces Cellmid’s comprehensive intellectual property position in using MK therapeutically,” chief executive officer Maria Halasz said.

“Through several global patent families Cellmid’s patent coverage now extends across a number of related mechanisms of action.”

Head of product development Darren Jones added that midkine could become an important agent in the treatment of heart failure.

“In an acute setting MK prevents cardiomyocyte death at the time of the heart attack. In the longer term MK promotes beneficial fibrosis and angiogenesis in the cardiac muscle in the weeks following a heart attack,” he said.


The U.S. patent provides further protection for Cellmid’s midkine treatment for heart failure.

This demonstrates the company’s intellectual property leadership in several therapeutic areas which could give rise to a strong pipeline and multiple licensing opportunities.

Its intellectual property portfolio includes 87 patents in 20 patent families, which cover the use of MK and anti-MK agents for therapeutic purposes in a number of diseases as well as a diagnostic marker in cancer and other disorders.

This will follow on Cellmid’s well established track record of deal making, including the cancer diagnostic licenses that are generating revenue already and the recently signed agreement with Zoetis, the largest animal health company in the world.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Cellmid Limited

Price: 0.12 AUD

Market: ASX
Market Cap: $15.03 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from...



Cellmid Limited to supply rapid diagnostic tests to help in new pandemic

Cellmid Limited (ASX:CDY) CEO Maria Halasz tells Proactive's Andrew Scott they've signed an agreement to supply rapid diagnostic tests (RDT), with products expected to arrive in the country by early April. The test uses a virus-specific detection method that delivers results anywhere between...

on 30/3/20

3 min read